Journal Logo

Articles by B. Eichhorst

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY: S105

Tausch, E.; Bahlo, J.; Robrecht, S.; More

HemaSphere. 3:4, June 2019.

HIGH EFFICACY OF VENETOCLAX PLUS OBINUTUZUMAB IN PATIENTS WITH COMPLEX KARYOTYPE (CKT) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A PROSPECTIVE ANALYSIS FROM THE CLL14 TRIAL: S106

Al-Sawaf, O.; Lilienweiss, E.; Bahlo, J.; More

HemaSphere. 3:4-5, June 2019.

FIXED-DURATION VENETOCLAX PLUS OBINUTUZUMAB IMPROVES PROGRESSION-FREE SURVIVAL AND MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL AND COMORBIDITIES: S149

Fischer, K.; Al-Sawaf, O.; Bahlo, J.; More

HemaSphere. 3:26-27, June 2019.

FACTORS IMPACTING TREATMENT SELECTION IN TREATMENT-NAÏVE PATIENTS WITH CLL: A MULTICENTER STUDY: PF381

Rhodes, J.; Sail, K.; Yazdy, Sarraf M.; More

HemaSphere. 3:142, June 2019.

IMPACT OF MAJOR GENOMIC ALTERATIONS ON OUTCOME OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX PLUS RITUXIMAB IN THE PHASE 3 MURANO STUDY: PS1123

Wu, J.; Bolen, C.; Seymour, J. F.; More

HemaSphere. 3:508-509, June 2019.